Currax acquires Nalpropion, gaining weight-loss medicine Contrave
Currax Pharmaceuticals LLC acquired 2018 start-up Nalpropion Pharmaceuticals Inc.. gaining worldwide rights to Nalpropion's sole product, the FDA-approved Contrave (bupropion/naltrexone; sold in the EU as Mysimba) weight-loss medication.
- Acquisition of Private Biotech
- Full Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.